TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03765060

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Monomax® 2/0 HR26
Description: It will be use a very long-term monofilament absorbable synthetic suture of Poly-4-hydroxybutyrate (Monomax) 2/0 with HR 26 needle.~In the technique should be given at least 2 points for each wound cm, with a distance to the alba line of 0'5cm and 0'5 cm of separation between stitches. The closure starts from both ends, ending in the middle of the laparotomy with an overlap of at least 2 cm. The ratio between the length of the suture and the length of the wound should be at least 4:1.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Monomax® 1 HR48
Description: It will be use a very long-term monofilament absorbable synthetic suture of Poly-4-hydroxybutyrate (Monomax) 1 with HR 48 needle.~In the technique should be given 1 point for each wound cm, with a distance to the alba line of 1 cm and 1 cm of separation between stitches. The closure starts from both ends, ending in the middle of the laparotomy with an overlap of at least 2 cm. The ratio between the length of the suture and the length of the wound should be at least 4:1.
Study: NCT03478371

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tampon D
Description: regular absorbency tampon

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tampon M
Description: regular absorbency tampon

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tampon T
Description: regular absorbency tampon

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tampon V
Description: regular absorbency tampon
Study: NCT02935569

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Compression HeadBand
Description: * commercially available office rubber bands (Alliance® Sterling Rubber Bands, Size 105) OR commercially available medical non-latex bands (Allegience® 1 x 18 x .025) with Velcro adhesion~* Plastics disks, hollow (3.5 cm diameter, by 1 cm height)~Two bands will be placed just behind the ears laterally, and over the occipital protuberance posteriorly. The plastic inserts will be placed in the temporal fossae bilaterally, under the band to provide adequate tension on the temporal artery.
Study: NCT05673356

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arthroscopic anterior cruciate ligament reconstruction with quadriceps tendon bone autograft (QTB)
Description: Arthroscopic anterior cruciate ligament reconstruction with quadriceps tendon bone autograft (QTB) will be performed in these patients. QTB autografts will be harvested as described in the published technique: K. Malinowski, J. Paszkowski, M. Mostowy, A. Góralczyk, R.F. LaPrade, K. Hermanowicz, Quadriceps Tendon-Bone Full-Thickness Autograft: Reproducible and Easy Harvesting Technique Using Simple Surgical Tools, Arthrosc. Tech. 10 (2021) e1165-e1172. https://doi.org/10.1016/j.eats.2021.01.003. ACLR will be performed utilizing anteromedial technique with management of any accompanying intraarticular lesions.
Study: NCT00564941

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: deferasirox
Study: NCT03308240

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Magic Therapy
Description: As described in the arm description
Study: NCT04419857

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High-calorie formula
Description: Infant randomly assigned to high-calorie formula for 14 days
Study: NCT02667925

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intraperitoneal cisplatin with nanocis
Description: Patients will receive an intraperitoneal chemotherapy combined to a radiotracer in order to assess the intraperitoneal distribution of the chemotherapy
Study: NCT04633746

Intervention type: DIAGNOSTIC_TEST
Intervention: measuring plasma Endostatin level
Description: measuring plasma Endostatin level at the time of admission then after 48hrs and 96 hours

Intervention type: DIAGNOSTIC_TEST
Intervention: measuring plasma Endostatin level
Description: measuring plasma Endostatin level at the time of admission then after 48hrs and 96 hours
Study: NCT03573037

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral anticoagulant
Description: 1:1 randomization to 1-month anticoagulation or 2-month anticoagulation after radiofrequency catheter ablation of paroxismal atrial fibrillation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral anticoagulant
Description: 1:1 randomization to 1-month anticoagulation or 2-month anticoagulation after radiofrequency catheter ablation of paroxismal atrial fibrillation
Study: NCT03954093

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Description: tDCS produces hyper/hypopolarizing potentials in the cortex underlying the scalp electrodes and can increase/decrease the excitability of targeted brain regions.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial direct current stimulation
Description: tDCS produces hyper/hypopolarizing potentials in the cortex underlying the scalp electrodes and can increase/decrease the excitability of targeted brain regions.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial direct current stimulation
Description: tDCS produces hyper/hypopolarizing potentials in the cortex underlying the scalp electrodes and can increase/decrease the excitability of targeted brain regions.
Study: NCT03303495

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 5 mg/kg intravenously administered over 90 minutes (can be reduced to 30 minutes at the minimum) on day 1 of a 2-week cycle.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 5 mg/kg intravenously administered over 90 minutes (can be reduced to 30 minutes at the minimum) on day 1 of a 2-week cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPT-11
Description: 180 mg/m2 intravenously administered over 90 minutes on day 1 of a 2-week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPT-11
Description: 180 mg/m2 intravenously administered over 90 minutes on day 1 of a 2-week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU Bolus
Description: 400 mg/m2 intravenous bolus on day 1 of a 2-week cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU Infusion
Description: 2400 mg/m2 continuous infusion over 46 hours on day 1 and 2 of a 2-week cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: l-LV (dl-LV)
Description: 200 (dl-LV: 400) mg/m2 intravenously administered over 120 minutes on day 1 of a 2-week cycle.
Study: NCT01776970

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cannabis Sativa extract Oromucosal spray
Description: Comparison between active drug (Cannabis Sativa extract Oromucosal spray, containing THC (27 mg/ml):CBD (25 mg/ml) vs placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis Sativa extract Oromucosal spray
Description: Comparison between active drug (Cannabis Sativa extract Oromucosal spray, containing THC (27 mg/ml):CBD (25 mg/ml) vs placebo
Study: NCT01558219

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cabacitaxel
Description: Jevtana® (cabazitaxel) 16 mg/m2 IV in 1 hour on day 1 given every second week
Study: NCT01656395

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1029
Description: MK-1029 10 mg, 30 mg or 150 mg oral tablets taken QD at bedtime, based on randomization.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1029
Description: MK-1029 10 mg, 30 mg or 150 mg oral tablets taken QD at bedtime, based on randomization.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1029
Description: MK-1029 10 mg, 30 mg or 150 mg oral tablets taken QD at bedtime, based on randomization.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1029
Description: MK-1029 10 mg, 30 mg or 150 mg oral tablets taken QD at bedtime, based on randomization.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1029
Description: MK-1029 10 mg, 30 mg or 150 mg oral tablets taken QD at bedtime, based on randomization.
Study: NCT01468181

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2189265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2189265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2189265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfonylureas (SU)
Description: SU is a pre-study prescribed dose and is not being provided as part of the trial.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biguanides (BG)
Description: Biguanides is a pre-study prescribed dose and is not being provided as part of the trial.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alpha-glucosidase inhibitor (a-GI)
Description: a-GI is a pre-study prescribed dose and is not being provided as part of the trial.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiazolidinedione (TZD)
Description: TZD is a pre-study prescribed dose and is not being provided as part of the trial.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glinides
Description: Glinides is a pre-study prescribed dose and is not being provided as part of the trial.
Study: NCT03591653

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LXI-15028
Description: The investigational products are administrated orally, once in the morning every day, and each dose includes one tablet of investigational products (LXI-15028 50mg active agent or placebo). If the investigational product is not taken in the morning, subjects can take it before 6:00 p.m. on the same day. The duration of treatment is 4 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01940133

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PQR309
Description: Dosing will be orally, once a day for the duration of the trial.
Study: NCT03529682

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: 10 minutes warm-up exercises and stretching exercises, 40 mınutes consecutive exercises (strengthening exercises for trunk and lower extremities) and 10 mınutes cooling down exercises and stretching exercises will be applied.

Intervention type: OTHER
Group type: OTHER
Intervention: control group
Description: 60 mınutes in a day and 3 times in a week traditional physiotherapy program will be applied
Study: NCT01656395

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Montelukast 10 mg
Description: Parts I-II: Participants will receive Montelukast 10 mg tablets QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg
Description: Parts I-II: Participants will receive Montelukast 10 mg tablets QD

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Parts I-II: Participants will receive Placebo tablets QD
Study: NCT03871153

Intervention type: DEVICE
Group type: OTHER
Intervention: Durvalumab
Description: Neoadjuvant Durvalumab 750 mg IV on Days 1, 15 and 29~Adjuvant Durvalumab 12 weeks after undergoing surgical resection 1,500 mg IV on Day 1

Intervention type: DRUG
Group type: OTHER
Intervention: Paclitaxel
Description: Paclitaxel 45 mg/m2 IV Days 1, 8, 15, 22, 29 and +/- 36

Intervention type: DRUG
Group type: OTHER
Intervention: Carboplatin
Description: Carboplatin AUC of 2 IV Days 1, 8, 15, 22, 29 +/- 36

Intervention type: RADIATION
Group type: OTHER
Intervention: Radiation
Description: 1.8-2.0 Gy per day (5 days/week) for a total of 45-61.2 Gy over 5-6 weeks. Treatment will be delivered using IMRT or 3DCRT using typically 6-10MV photons. Proton therapy is also allowed. 4D simulation and appropriate IGRT are encouraged. Radiation therapy must begin within one week of the first day of chemotherapy (or vice versa).
Study: NCT04293458

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EsoGuard
Description: EsoGuard assay (LDT) will be used on cells collected using EsoCheck (510K cleared esophageal cell collection device) and compared to results of EGD plus biopsies (when taken)
Study: NCT01827644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afuresertib GC - Fasted State
Description: White opaque hard gelatin capsule containing afuresertib 25 mg. Subjects will receive single oral dose of afuresertib GC administered in fasted state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afuresertib GC - Fasted State
Description: White opaque hard gelatin capsule containing afuresertib 25 mg. Subjects will receive single oral dose of afuresertib GC administered in fasted state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afuresertib GC - Fasted State
Description: White opaque hard gelatin capsule containing afuresertib 25 mg. Subjects will receive single oral dose of afuresertib GC administered in fasted state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afuresertib GC - Fasted State
Description: White opaque hard gelatin capsule containing afuresertib 25 mg. Subjects will receive single oral dose of afuresertib GC administered in fasted state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afuresertib HPMC capsule - Fasted State
Description: White opaque HPMC capsule containing afuresertib 25 mg. Subjects will receive single oral dose of afuresertib HPMC capsule administered in fasted state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afuresertib HPMC capsule - Fasted State
Description: White opaque HPMC capsule containing afuresertib 25 mg. Subjects will receive single oral dose of afuresertib HPMC capsule administered in fasted state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afuresertib HPMC capsule - Fasted State
Description: White opaque HPMC capsule containing afuresertib 25 mg. Subjects will receive single oral dose of afuresertib HPMC capsule administered in fasted state
Study: NCT03871153

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Surgical Resection
Description: Patients will undergo repeat imaging between 4 and 12 weeks after completing neoadjuvant therapy. Those without evidence of progressive disease and found to be a surgical candidate by a thoracic surgeon will undergo surgical resection between 4 and 12 weeks after neoadjuvant therapy.
Study: NCT04503967

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib Hydrochloride With Nivolumab
Description: Anlotinib Hydrochloride Combined With Nivolumab in the second line Treatment of Gastric and Esophageal Cancer patients
Study: NCT03669549

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nevanimibe hydrochloride
Description: During the 16-week treatment period, all subjects will begin dosing with nevanimibe HCl 500 mg BID and be dose titrated to 1000 mg BID, 1500 mg BID, and 2000 mg BID as needed based on serum 17-OHP assessments every 4 weeks.
Study: NCT02168491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lixisenatide
Description: Patients will be switched to basal insulin glargine (Lantus, once daily in the morning) and GLP-1 receptor agonist Lixisenatide (Lyxumia, once daily in the morning before breakfast; days 1-14 10 µg thereafter 20 µg). The (mean) daily dose of premixed insulin will be calculated based on the records of the run in period. The initial dose of insulin glargine will be adjusted at about 60% of the daily insulin dose of premixed insulin. This is based on the observed reduction of required insulin dose described in recent literature upon initiation with a GLP-1 agonist.
Study: NCT01012297

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: Given SC

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Given IV
Study: NCT02235311

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pantoprazole
Description: Pantoprazole 40mg orally daily x 8 weeks after acute management of UGIB

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pantoprazole
Description: Pantoprazole 40mg orally daily x 8 weeks after acute management of UGIB
Study: NCT02861235

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stress thallium-201 tomoscintigraphy, followed by a second rest tomoscintigraphy if necessary
Description: with gamma-camera and D.SPECT camera

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rest technetium-99m tomoscintigraphy followed by stress technetium-99m tomoscintigraphy on the same day
Description: with gamma-camera and D.SPECT camera, in Toulouse centre

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stress technetium-99m tomoscintigraphy followed by rest technetium-99m tomoscintigraphy on the same day
Description: with gamma-camera and D.SPECT camera, in Nancy centre

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: stress technetium-99m tomoscintigraphy followed by rest technetium-99m tomoscintigraphy in two different days
Description: with gamma-camera and D.SPECT camera, in Paris centre

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rest thallium-201 tomoscintigraphy with gamma-camera and D.SPECT camera
Description: rest thallium-201 tomoscintigraphy for myocardial viability assessment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rest technetium-99m tomoscintigraphy with gamma-camera and D.SPECT camera
Description: rest technetium-99m tomoscintigraphy for myocardial viability assessment
Study: NCT04684017

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib hydrochloride
Description: anlotinib 10 mg/day orally (from days 1 to 14 in a 21-day cycle)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 100mg/m2 iv on days 1-3 every 21 days for 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 5 iv on day 1 every 21 days for 4 cycles
Study: NCT03776539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ELX-02
Description: ELX-02 is a synthetic, designer eukaryotic ribosomal specific glycoside (ERSG) optimized as a translational read-through drug. All groups will get the same treatment.
Study: NCT01368029

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GG ATCC 53103 (LGG)
Description: Study drug capsules (1x10\^10 LGG/capsule) are to be taken orally twice a day every day on an outpatient basis for 28 days

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules composed of microcrystalline cellulose are to be taken orally twice a day on an outpatient basis for 28 days.
Study: NCT05249738

Intervention type: DIAGNOSTIC_TEST
Intervention: Measuring tongue cross-sectional area by submental ultrasonography
Description: The tongue cross-sectional areas of both groups were measured with submental ultrasonography to detect tongue edema.

Intervention type: DIAGNOSTIC_TEST
Intervention: Measuring tongue cross-sectional area by submental ultrasonography
Description: The tongue cross-sectional areas of both groups were measured with submental ultrasonography to detect tongue edema.
Study: NCT03014479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trelagliptin
Description: Trelagliptin 100 mg or 50 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daily DPP-4 inhibitor
Description: Alogliptin, anagliptin, linagliptin, saxagliptin, sitagliptin, teneligliptin or vildagliptin
Study: NCT02108964

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EGF816
Description: EGF816 will be dosed once daily. On the first day of each treatment cycle, the patient receives an adequate drug supply for self-administration at home. The investigator will instruct the patient to take EGF816 exactly as prescribed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EGF816
Description: EGF816 will be dosed once daily. On the first day of each treatment cycle, the patient receives an adequate drug supply for self-administration at home. The investigator will instruct the patient to take EGF816 exactly as prescribed.
Study: NCT02168491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glargine
Description: Patients will be switched to basal insulin glargine (Lantus, once daily in the morning) and GLP-1 receptor agonist Lixisenatide (Lyxumia, once daily in the morning before breakfast; days 1-14 10 µg thereafter 20 µg). The (mean) daily dose of premixed insulin will be calculated based on the records of the run in period. The initial dose of insulin glargine will be adjusted at about 60% of the daily insulin dose of premixed insulin. This is based on the observed reduction of required insulin dose described in recent literature upon initiation with a GLP-1 agonist.
Study: NCT00984932

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: 40 mg of rosuvastatin daily